Development Policy Blog

MMV's CEO, David Reddy, speaks about partnerships and innovation to defeat malaria.

Latest science article

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria


Funding will unlock the Pathogen Box’s potential to discover novel drugs for diseases of poverty 

19 August 2015

MMV partners with the Social Media Awards 2015

13 August 2015

Technical brief presents recommendations for the control and elimination of P. vivax malaria

29 July 2015

PATH report selects OZ439 for its promise as a synthetic antimalarial drug candidate

16 July 2015